Show simple item record

dc.contributor.authorScholefield, JHen_US
dc.contributor.authorMoss, Sen_US
dc.contributor.authorSufi, Fen_US
dc.contributor.authorMangham, CMen_US
dc.contributor.authorHardcastle, JDen_US
dc.identifier.citationGUT, 2002, 50 pp. 840 - 844en_US
dc.description.abstractBackground: Three large randomised trials have shown that screening for colorectal cancer using faecal occult blood (FOB) tests can reduce the mortality from this disease. Two national pilot studies have recently been launched in the UK to investigate the feasibility of population screening for colorectal cancer in the National Health Service. The largest of the randomised trials was conducted in Nottingham and randomised 152 850 individuals between the ages of 45 and 74 years to receive biennial Haemoccult (FOB) test kit (intervention group) or to a control group. Aims: We have compared the mortality in the intervention group compared with the control group. Methods: The 152 850 randomised individuals were followed up through local health records and central flogging (Office for National Statistics) over a median follow up period of 11 years. Results: At a median follow up of 11 years there was a 13% reduction in colorectal cancer mortality (95% confidence interval 3-22%) in the intervention group despite an uptake at first invitation of only approximately 50%. The mortality reduction for those accepting screening was 27%. The reduction in mortality was independent of sex and site of tumour. There was no significant difference in mortality from causes other than colorectal cancer between the intervention and control groups. Conclusions: Although the reduction in colorectal cancer mortality was sustained, further follow up of this population is required to determine whether a significant reduction in the incidence of colorectal cancer will be achieved.en_US
dc.format.extent840 - 844en_US
dc.titleEffect of faecal occult blood screening on mortality from colorectal cancer: results from a randomised controlled trialen_US
dc.typeJournal Article
rioxxterms.typeJournal Article/Reviewen_US
pubs.notesaffiliation: Scholefield, JH (Reprint Author), Univ Nottingham Hosp, Div GI Surg, Nottingham NG7 2UH, England. Univ Nottingham Hosp, Div GI Surg, Nottingham NG7 2UH, England. Canc Screening Evaluat Unit, Sutton SM2 5NG, Surrey, England. keywords-plus: SIGMOIDOSCOPY research-areas: Gastroenterology & Hepatology web-of-science-categories: Gastroenterology & Hepatology number-of-cited-references: 18 times-cited: 185 usage-count-last-180-days: 0 usage-count-since-2013: 3 journal-iso: Gut doc-delivery-number: 555UT unique-id: ISI:000175812200019 oa: gold_or_bronze da: 2018-09-17en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams/Cancer Screening Evaluation Unit (DoH)
pubs.embargo.termsNot knownen_US
icr.researchteamCancer Screening Evaluation Unit (DoH)en_US
dc.contributor.icrauthorMoss, Susan Maryen_US

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record